Abstract: Objective This study aimed to investigate clinical efficacy of endoscopic therapy in combination with somatostatin or terlipressin in treatment of patients with hepatitis B-induced liver cirrhosis (LC) and esophagogastric variceal bleeding (EVB). Methods Forty-eight patients with hepatitis B-induced LC and EVB were encountered in our hospital between June 2022 and June 2025, and all underwent endoscopic variceal ligation or tissue glue injection. Intravenous somatostatin was given in 22 cases (observation group) or terlipressin was given in 26 cases (control group). Esophagogastric varices (EV) grading was evaluated by gastroscopy, and Child-Pugh and MELD scores were obtained routinely. Results Initial hemostasis, hemostasis at 24 hours and at 72 hours in the observation group were 50.0%, 95.5% and 100.0%, all significantly higher than 34.6%, 76.9% and 84.6%, while red blood cell suspension infused was (2.1±0.9)U, significantly less than [(3.4±1.2)U, P<0.05] in the control group; re-examination of gastroscopy found improved EV grading in the observation group was 77.3%, much higher than 53.8% in the control group(P<0.05); decreased Child-Pugh and MELD scores in the observation group were (-0.9±0.4) and (-1.8±0.7), both much higher than [(-0.3±0.1) and (-0.6±0.3), respectively, P<0.05], while incidence of hepatic encephalopathy, 30-day re-bleeding and 30-day mortality were 4.5%, 9.1% and 4.5%, all much lower than 19.2%, 30.8% and 30.8%(P<0.05), and hospital stay was (10.2±2.1)d, much shorter than [(13.5±2.8)d, P<0.05] in the control group. Conclusion Emergency endoscopic therapy followed by intravenous somatostatin or terlipressin administration in dealing with patients with LC and EVB is certainly efficacious, with high successful hemostasis and short-term survivals.

Key words: Liver cirrhosis, Esophagogastric variceal bleeding, Somatostatin, Terlipressin, Endoscopic varices ligation, Therapy